biOasis Technologies Ord Shs V.BTI.H

RE:Bottom Line: xB3 never in a stronger position

[prophetoffactz]

C$12 billion per year is HUGE! Then comes the xB3 pipeline, and Q-Sphera, etc.

"Total all markets up and Biodexa's clinical trial programs address markets potentially worth over C$12 billion per year and growing."

prophetoffactz wrote:

The new merged company, Biodexa:

1) Control of xB3. 

2) Clinical trial infrastructure to advance therapeutics itself and to enter into more meaningful strategic alliances later in the development process adding value.
3) US NASDAQ listing.
4) Backing of US Ladenberg Thalmann. According to Wikepedia Ladenberg Thalmann has 4,000 financial advisors and manages US$125 billion in client assets.
5) Has cash and with additional deals anticipated potentially more cash soon. There is 1 1/2 months until the expiration of the J&J option. Neuremedy has an option that can be exercised and monitized. There are also potential milestone payments from partners as well as warrants and options.
6) Biodexa has multiple clinical stage assets that can support news flow and hard data valuation milestones while xB3 advances to the clinic over the next two years. The glioblastoma market is expected to be worth C$5.67 billion per year in 2028. The Optic Neuritis market is C$275 million in 2022. Guillian-Bar therapy market is expected to be C$917 million in 2027. CIDP therapy market is expected to be C$5.265 billion at the end of 2023. Total all markets up and Biodexa's clinical trial programs address markets potentially worth over C$12 billion per year and growing.
7) Biodexa's Q-Sphera has two deals with J&J. News release, "On 17 June 2021 the Company announced that, using its Q-Sphera technology, it had successfully encapsulated a proprietary Janssen experimental large molecule medicine and importantly preserved its functional integrity. The Company believes no other commercial or academic organisation has been able to successfully deliver any such experimental medicine over extended periods using methods capable of commercial scaling".
8) Hunter is reaffirmed as xB3's lead asset in the merger. If Chiesi encountered a roadblock would Hunter, which is also an LSD, be nominated as xB3's lead assets? Chiesi recently submitted Fabry for US FDA approval and expects approval in 2023 making it a strategic player in the LSD space. Biodexa will be presenting preclinical Hunter data in Q2 2023. What's this new data about given the previous data BTI has presented? Do we have improved second-generation LSD asset to take on Denali which has helped prove LSDs in humans? Could Biodexa leap-frog Denali? Biodexa has the capability to advance clinical trials itself. Biodexa could enter a more substantive strategic deal with Chiesi in the LSD and even rare disease space. Oxyrane also has an interesting potential LSD opportunity.
9) Biodexa has cancer assets and expertise that could be used with xB3 that may support an interesting strategic alliance in cancer or combination therapies.

Saltarelli has moved to the Board of the new company. He has been with a number of biotech success stories as well as with big biotech and big pharma.